Deadline Approaches for Reckitt Benckiser Class Action Lawsuit

Categories: Louisiana Business NewsLouisiana HealthcareLouisiana LifestyleLouisiana News

The legal framework surrounding the Reckitt Benckiser class action lawsuit.

News Summary

Investors looking to join the securities class action lawsuit against Reckitt Benckiser Group PLC must file lead plaintiff applications by August 4, 2025. The lawsuit alleges that Reckitt failed to disclose risks related to their Enfamil formula, impacting investor decisions. Kahn Swick & Foti, LLC encourages eligible investors to seek guidance on their legal rights without any obligation. KSF is recognized for its success in securities litigation, catering to both institutional and retail investors affected by corporate misconduct.

New York – Investors interested in participating in the securities class action lawsuit against Reckitt Benckiser Group PLC have a critical deadline approaching. Kahn Swick & Foti, LLC (KSF) has announced that the deadline for filing lead plaintiff applications is set for August 4, 2025.

Eligible investors include those who purchased Reckitt’s American Depositary Shares (ADSs) between January 13, 2021, and July 28, 2024. The lawsuit is currently pending in the United States District Court for the Southern District of New York under the case titled Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., No. 25-cv-4708.

The allegations made against Reckitt and certain executives assert that they failed to disclose significant material information during the Class Period, which constitutes a violation of federal securities laws. Specifically, the lawsuit claims that Reckitt neglected to inform investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants associated with their cow’s milk-based formula, Enfamil. This failure to disclose could potentially harm the company’s sales of Enfamil and expose it to legal claims. Moreover, the complaint asserts that any positive statements made by the company regarding its business operations and prospects were materially false and misleading or lacked a reasonable basis.

As the deadline approaches, KSF is encouraging affected investors to come forward and seek guidance on their legal rights related to the case. Investors can reach out to KSF Managing Partner Lewis Kahn for assistance either through a toll-free number at 1-877-515-1850 or via email at lewis.kahn@ksfcounsel.com. Notably, there is no obligation or cost for investors to discuss their rights or this case with KSF.

KSF is widely recognized as a leading boutique securities litigation law firm in the United States with a proven track record of success. The firm operates offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and also maintains a representative office in Luxembourg. KSF has topped the rankings among plaintiff law firms nationwide, achieving recognition among the top 10 based on total settlement value, according to SCAS.

The firm’s mission involves serving both institutional and retail investors who are seeking recoveries for investment losses stemming from corporate fraud and misconduct. KSF is committed to advocating for the rights of investors who have been affected by deceptive practices in the corporate sector.

For investors who believe they are affected and eligible to participate in the lawsuit against Reckitt Benckiser, the upcoming deadline serves as a critical reminder. It emphasizes the importance of taking necessary actions to protect their investments.

In summary, the class action lawsuit against Reckitt spans over significant allegations related to the manufacturer’s disclosure failures regarding their product, which is vital information for concerned stakeholders. As the deadline for lead plaintiff applications looms, KSF continues to be at the forefront, offering assistance to investors navigating these complex legal proceedings and ensuring their rights are upheld.